华东医药:GLP-1/GIP双靶点长效激动剂HDM1005注射液新适应症中国IND获得批准

美港电讯
25 Feb

【华东医药:GLP-1/GIP双靶点长效激动剂HDM1005注射液新适应症中国IND获得批准】金十数据2月25日讯,华东医药股份有限公司宣布,公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》,由中美华东申报的HDM1005注射液临床试验申请获得批准,适应症为用于阻塞性睡眠呼吸暂停(OSA)合并肥胖或超重成人患者的治疗。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10